The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A novel NF- B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors
Abstract
Constitutive phosphorylation of c-kit tyrosine kinase is the major cause of factor-independent proliferation of mast cells. Recently available tyrosine kinase inhibitors have shown marked activity against mast cell lines that carry wild-type c-kit, and some, but not others, carry mutant c-kit. Here we clearly demonstrated that a novel NF-kappaB inhibitor, IMD-0354, restrained factor-independent proliferation of mast cells with c-kit mutations but not of normal mast cells. In HMC-1 cells with the Asp816Val and Val560Gly mutations, we found that NF-kappaB was constitutively activated without exogenous stimulation. When the DNA-binding activity of NF-kappaB was inhibited by treatment with IMD-0354, cell proliferation was completely suppressed. We detected the expression of cyclin D2, D3, and E in HMC-1 cells and observed that cyclin D3 expression was dramatically decreased by treatment with IMD-0354. Abolishing protein kinase C or phosphatidylinositol 3 kinase pathways also inhibited NF-kappaB translocation to the nucleus, indicating the involvement of these signaling cascades in NF-kappaB activation in HMC-1 cells. Our findings indicated that autophosphorylated c-kit receptors induced NF-kappaB activation, resulting in the up-regulation of cyclin D3 expression and cell cycle progression. The observations from the current study suggest a therapeutic potential, in systemic mastocytosis, for compounds that interfere with NF-kappaB signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuronal apoptosis at the G1/S cell cycle checkpoint
Liu, D. X., & Greene, L. A. (2001) · Cell and Tissue Research · doi:10.1007/s004410100396 · Cited by 234
Cited by
NF‐κB and the link between inflammation and cancer
DiDonato, J. A., Mercurio, F., & Karin, M. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01099.x · Cited by 1,482
Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression
Bassères, D. S., & Baldwin, A. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209942 · Cited by 667
Shah, N. P., Lee, F. Y., Luo, R., Jiang, Y., Donker, M., & Akin, C. (2006) · Blood · doi:10.1182/blood-2005-10-3969 · Cited by 273
Ppm1b negatively regulates necroptosis through dephosphorylating Rip3
Chen, W., Wu, J., Li, L., Zhang, Z., Ren, J., Liang, Y., Chen, F., Yang, C., Zhou, Z., Sean Su, S., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3120 · Cited by 161
Park, J., Choi, J., Son, D., Park, E., Song, M., Hellström, M., & Hong, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040738 · Cited by 97
“Moreover, NF-κB inhibitor, IMD-0354 inhibited abnormal proliferation of mast cells, and reduced the allergic response [15].”
Metadata
- Authors
- Tanaka, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2005-03-15
- Volume
- 105
- Issue
- 6
- Pages
- 2324-2331
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2011178313
- Cited by
- 162
- References
- 1
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A novel NF- B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. https://app.cochat.ai/papers/10.1182/blood-2004-08-3247
- The paper
- Tanaka, A. (2005). A novel NF- B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood. https://doi.org/10.1182/blood-2004-08-3247
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.